![]() The trial is expected to begin in the third quarter, the company said. Each episode of the King County Local Dive podcast features original watchdog reporting from our local journalists with a focus on how we hold our public entities and public officials accountable. In June, Sonoma received Food and Drug Administration permission to begin human testing of a fusion protein drug candidate that’s designed to be used as a “preconditioning” regimen ahead of Treg cell treatment. The company signed a “long-term” lease for the site, which is located on the Seattle waterfront. Sonoma said its facility would include capabilities for cell selection, genetic modification and automated manufacturing. “Seattle has an established legacy of delivering many firsts in the cell therapy field for cancer, and we are building upon those insights to advance our pipeline of engineered Treg therapies for autoimmune and inflammatory diseases,” said Bluestone, in a statement. Experience November 2014 - Present San Joaquin Soccer Alliance September 2011 - Present CrowdSporting January 2014 - December 2014 iDive Housing February 2013 - January 2014 Koltai & Co. Sonoma is based in South San Francisco, but it chose Seattle for its new manufacturing center in part because of the area’s history with cell therapy. It’s one of a handful of startups exploring Tregs, which have also begun to draw attention from larger pharmaceutical companies.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |